Rani Therapeutics (RANI) Competitors $0.41 -0.02 (-4.83%) As of 01:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RANI vs. CRBU, NXTC, IPHA, LFVN, IMRX, ENTA, SPRO, LXEO, THTX, and GLSIShould you be buying Rani Therapeutics stock or one of its competitors? The main competitors of Rani Therapeutics include Caribou Biosciences (CRBU), NextCure (NXTC), Innate Pharma (IPHA), Lifevantage (LFVN), Immuneering (IMRX), Enanta Pharmaceuticals (ENTA), Spero Therapeutics (SPRO), Lexeo Therapeutics (LXEO), Theratechnologies (THTX), and Greenwich LifeSciences (GLSI). These companies are all part of the "pharmaceutical products" industry. Rani Therapeutics vs. Its Competitors Caribou Biosciences NextCure Innate Pharma Lifevantage Immuneering Enanta Pharmaceuticals Spero Therapeutics Lexeo Therapeutics Theratechnologies Greenwich LifeSciences Rani Therapeutics (NASDAQ:RANI) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations. Does the media prefer RANI or CRBU? In the previous week, Rani Therapeutics had 5 more articles in the media than Caribou Biosciences. MarketBeat recorded 6 mentions for Rani Therapeutics and 1 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 1.71 beat Rani Therapeutics' score of 0.78 indicating that Caribou Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Rani Therapeutics Positive Caribou Biosciences Very Positive Is RANI or CRBU more profitable? Rani Therapeutics has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,490.84%. Caribou Biosciences' return on equity of -55.70% beat Rani Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Rani TherapeuticsN/A -1,258.76% -80.52% Caribou Biosciences -1,490.84%-55.70%-45.35% Do institutionals & insiders believe in RANI or CRBU? 30.2% of Rani Therapeutics shares are owned by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are owned by institutional investors. 45.1% of Rani Therapeutics shares are owned by insiders. Comparatively, 9.5% of Caribou Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more risk & volatility, RANI or CRBU? Rani Therapeutics has a beta of -0.02, suggesting that its share price is 102% less volatile than the S&P 500. Comparatively, Caribou Biosciences has a beta of 2.48, suggesting that its share price is 148% more volatile than the S&P 500. Do analysts prefer RANI or CRBU? Rani Therapeutics presently has a consensus price target of $7.33, indicating a potential upside of 1,706.24%. Caribou Biosciences has a consensus price target of $8.50, indicating a potential upside of 373.54%. Given Rani Therapeutics' higher possible upside, analysts plainly believe Rani Therapeutics is more favorable than Caribou Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rani Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Caribou Biosciences 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better earnings & valuation, RANI or CRBU? Rani Therapeutics has higher earnings, but lower revenue than Caribou Biosciences. Caribou Biosciences is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRani Therapeutics$1.03M24.92-$30.02M-$0.99-0.41Caribou Biosciences$9.99M16.71-$149.10M-$1.62-1.11 SummaryRani Therapeutics beats Caribou Biosciences on 8 of the 15 factors compared between the two stocks. Get Rani Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RANI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RANI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RANI vs. The Competition Export to ExcelMetricRani TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.66M$2.92B$5.56B$9.30BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-0.4120.3528.6119.64Price / Sales24.92304.32437.49188.30Price / CashN/A43.1536.0257.93Price / Book6.777.718.185.63Net Income-$30.02M-$55.11M$3.23B$257.73M7 Day Performance-38.57%0.68%-0.25%0.07%1 Month Performance-21.94%8.22%5.40%8.32%1 Year Performance-89.72%-2.64%26.35%13.78% Rani Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RANIRani Therapeutics1.9818 of 5 stars$0.41-4.8%$7.33+1,706.2%-89.2%$25.66M$1.03M-0.41110News CoverageCRBUCaribou Biosciences2.9088 of 5 stars$1.70+4.3%$8.50+400.0%-24.4%$158.11M$9.92M-1.05100Positive NewsNXTCNextCure4.3475 of 5 stars$4.90+3.4%$3.50-28.6%-76.2%$157.34MN/A-2.7890Analyst ForecastGap UpHigh Trading VolumeIPHAInnate Pharma2.6049 of 5 stars$1.70-2.5%$11.00+547.1%-16.5%$156.71M$21.77M0.00220Positive NewsLFVNLifevantage4.3467 of 5 stars$12.38+3.1%$30.50+146.4%+102.6%$155.86M$200.16M17.94260News CoveragePositive NewsIMRXImmuneering3.2597 of 5 stars$4.17-5.7%$13.25+217.7%+242.6%$150.06MN/A-2.1360ENTAEnanta Pharmaceuticals3.9191 of 5 stars$6.96+6.1%$18.00+158.6%-60.2%$148.81M$67.64M-1.53160News CoveragePositive NewsSPROSpero Therapeutics3.9004 of 5 stars$2.64-6.0%$5.00+89.4%+72.3%$147.60M$47.98M-2.06150Positive NewsLXEOLexeo Therapeutics2.0196 of 5 stars$4.44-0.7%$16.60+273.9%-68.3%$147.41M$650K-1.3558Gap UpTHTXTheratechnologiesN/A$3.15flatN/A+103.9%$144.84M$85.87M-16.58140Earnings ReportGLSIGreenwich LifeSciences2.1494 of 5 stars$10.81-0.3%$39.00+260.8%-35.6%$144.53MN/A-8.583Positive NewsHigh Trading Volume Related Companies and Tools Related Companies CRBU Alternatives NXTC Alternatives IPHA Alternatives LFVN Alternatives IMRX Alternatives ENTA Alternatives SPRO Alternatives LXEO Alternatives THTX Alternatives GLSI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RANI) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredAll New Social Security Numbers coming July 23?To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rani Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rani Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RANI Stock Alerts